Advertisement
U.S. markets close in 4 hours 49 minutes
  • S&P 500

    5,251.06
    +2.57 (+0.05%)
     
  • Dow 30

    39,722.34
    -37.74 (-0.09%)
     
  • Nasdaq

    16,392.85
    -6.67 (-0.04%)
     
  • Russell 2000

    2,130.23
    +15.88 (+0.75%)
     
  • Crude Oil

    82.71
    +1.36 (+1.67%)
     
  • Gold

    2,234.40
    +21.70 (+0.98%)
     
  • Silver

    25.00
    +0.25 (+1.00%)
     
  • EUR/USD

    1.0798
    -0.0032 (-0.29%)
     
  • 10-Yr Bond

    4.1960
    0.0000 (0.00%)
     
  • dólar/libra

    1.2627
    -0.0011 (-0.09%)
     
  • USD/JPY

    151.2860
    +0.0400 (+0.03%)
     
  • Bitcoin USD

    71,257.54
    +1,472.74 (+2.11%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,972.37
    +40.39 (+0.51%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

Amgen Phase lll PAVES Study evaluating Neulasta met primary endpoint

Amgen announced results from Pegfilgrastim and Anti-VEGF Evaluation Study, PAVES, a Phase 3 trial which evaluated Neulasta (pegfilgrastim) in 845 patients receiving FOLFOX or FOLFIRI and bevacizumab for the first-line treatment of locally-advanced or metastatic colorectal cancer. FOLFOX and FOLFIRI are two of the most commonly used chemotherapy regimens for colorectal cancer. The study met its primary endpoint, with Neulasta significantly reducing the incidence of febrile neutropenia. Febrile neutropenia is a low white blood cell count accompanied by a fever.

Advertisement